219 related articles for article (PubMed ID: 31930332)
1. APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen receptor status.
Udquim KI; Zettelmeyer C; Banday AR; Lin SH; Prokunina-Olsson L
Carcinogenesis; 2020 Aug; 41(8):1030-1037. PubMed ID: 31930332
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3A is a prominent cytidine deaminase in breast cancer.
Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
[TBL] [Abstract][Full Text] [Related]
3. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
Zhang Y; Delahanty R; Guo X; Zheng W; Long J
Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
Tsuboi M; Yamane A; Horiguchi J; Yokobori T; Kawabata-Iwakawa R; Yoshiyama S; Rokudai S; Odawara H; Tokiniwa H; Oyama T; Takeyoshi I; Nishiyama M
Breast Cancer; 2016 Sep; 23(5):780-8. PubMed ID: 26476745
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
[TBL] [Abstract][Full Text] [Related]
6. Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity.
Rouf Banday A; Onabajo OO; Lin SH; Obajemu A; Vargas JM; Delviks-Frankenberry KA; Lamy P; Bayanjargal A; Zettelmeyer C; Florez-Vargas O; Pathak VK; Dyrskjøt L; Prokunina-Olsson L
Commun Biol; 2021 Mar; 4(1):386. PubMed ID: 33753867
[TBL] [Abstract][Full Text] [Related]
7. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
[TBL] [Abstract][Full Text] [Related]
8. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
[TBL] [Abstract][Full Text] [Related]
9. APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer.
Periyasamy M; Patel H; Lai CF; Nguyen VTM; Nevedomskaya E; Harrod A; Russell R; Remenyi J; Ochocka AM; Thomas RS; Fuller-Pace F; Győrffy B; Caldas C; Navaratnam N; Carroll JS; Zwart W; Coombes RC; Magnani L; Buluwela L; Ali S
Cell Rep; 2015 Oct; 13(1):108-121. PubMed ID: 26411678
[TBL] [Abstract][Full Text] [Related]
10. Progressive APOBEC3B mRNA expression in distant breast cancer metastases.
Sieuwerts AM; Schrijver WA; Dalm SU; de Weerd V; Moelans CB; Ter Hoeve N; van Diest PJ; Martens JW; van Deurzen CH
PLoS One; 2017; 12(1):e0171343. PubMed ID: 28141868
[TBL] [Abstract][Full Text] [Related]
11. Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB.
Periyasamy M; Singh AK; Gemma C; Farzan R; Allsopp RC; Shaw JA; Charmsaz S; Young LS; Cunnea P; Coombes RC; Győrffy B; Buluwela L; Ali S
Oncogene; 2021 Feb; 40(6):1077-1090. PubMed ID: 33323971
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.
Cescon DW; Haibe-Kains B; Mak TW
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2841-6. PubMed ID: 25730878
[TBL] [Abstract][Full Text] [Related]
13. Genetic inhibitors of APOBEC3B-induced mutagenesis.
Mertz TM; Rice-Reynolds E; Nguyen L; Wood A; Cordero C; Bray N; Harcy V; Vyas RK; Mitchell D; Lobachev K; Roberts SA
Genome Res; 2023 Sep; 33(9):1568-1581. PubMed ID: 37532520
[TBL] [Abstract][Full Text] [Related]
14. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
[TBL] [Abstract][Full Text] [Related]
15. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
Vural S; Simon R; Krushkal J
Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
[TBL] [Abstract][Full Text] [Related]
16. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
17. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines.
Vladusic EA; Hornby AE; Guerra-Vladusic FK; Lakins J; Lupu R
Oncol Rep; 2000; 7(1):157-67. PubMed ID: 10601611
[TBL] [Abstract][Full Text] [Related]
18. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
Law EK; Sieuwerts AM; LaPara K; Leonard B; Starrett GJ; Molan AM; Temiz NA; Vogel RI; Meijer-van Gelder ME; Sweep FC; Span PN; Foekens JA; Martens JW; Yee D; Harris RS
Sci Adv; 2016 Oct; 2(10):e1601737. PubMed ID: 27730215
[TBL] [Abstract][Full Text] [Related]
19. Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines.
Hevir N; Trošt N; Debeljak N; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):206-16. PubMed ID: 21182832
[TBL] [Abstract][Full Text] [Related]
20. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
Sieuwerts AM; Willis S; Burns MB; Look MP; Meijer-Van Gelder ME; Schlicker A; Heideman MR; Jacobs H; Wessels L; Leyland-Jones B; Gray KP; Foekens JA; Harris RS; Martens JW
Horm Cancer; 2014 Dec; 5(6):405-13. PubMed ID: 25123150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]